Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4041424344454647484950...123124»
  • ||||||||||  A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC). (On Demand | Level 1, West Hall; Poster Board No. N9) -  Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_710;    
    P1
    In COSMIC-313, the triplet combination with cabozantinib (CABO)-ipilimumab (IPI)-nivolumab (NIVO) demonstrated promising efficacy compared to IPI-NIVO in pts with intermediate/poor risk disease, but definitive overall survival (OS) benefit has yet to be shown, and is associated with higher incidence of adverse events...Subsequent therapy is dependent on response, and can be NIVO 480mg IV Q4W (CR/PR/SD), lenvatinib 18mg + everolimus 5mg PO QD (PD on both prior regimens), or re-initiation of CABO 60mg PO QD (CR/PR/SD at CABO but PD on IPI-NIVO)...The trial is currently enrolling pts. Clinical trial information: NCT05188118.
  • ||||||||||  Review, Journal:  Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. (Pubmed Central) -  Jan 9, 2023   
    We found that the previously valued therapeutic effect of lenvatinib may be unsatisfactory; combining tyrosine kinase (TK) inhibitors (TKIs) with other agents results in a higher rate of clinical benefit...The AEs reported for all agents are relatively numerous but largely manageable clinically. More clinical trials are expected to further confirm the effectiveness and safety of these targeted drugs for ATC.
  • ||||||||||  Review, Journal, IO biomarker:  Molecular features of aggressive thyroid cancer. (Pubmed Central) -  Jan 7, 2023   
    These drugs not only can limit the cancer spread, but in some circumstance they are able to induce the re-differentiation of aggressive tumors, which can be again submitted to new attempts of RAI therapy. In this review we explore the current knowledge on the genetic landscape of TC and its implication on the development of new precise therapeutic strategies.
  • ||||||||||  The Rise of Medical Therapies for the Treatment of Hepatocellular Carcinoma (HCC) (Poster Hall ABC) -  Jan 6, 2023 - Abstract #SIR2023SIR_656;    
    The medications are significantly different; even in the same class and may affect IR procedures.Clinical Findings/Procedure Details:Current medical therapies available to treat HCC including multi-receptor tyrosine kinase inhibitors (sorafenib; regorafenib; lenvatinib; cabozantinib); monoclonal antibodies (ramucirumab and bevacizumab) which target vascular endothelial growth factor (VEGF); and immunotherapies (nivolumab; atezolizumab; pembrolizumab; durvalumab; tremelimumab)...Other medical therapies with phase 3 trial results such as tislelizumab and camrelizumab plus rivoceranib will be reviewed...Finally; we will review a single arm trial of combined neoadjuvant cabozantinib and nivolumab which converted 80% of non-resectable HCCs to successful resection.Conclusion and/or Teaching Points:Interventional Radiologists treating HCC need to stay abreast of the medical therapies available to HCC since the therapies are continuously expanding in number and combinations and may interplay with IR treatments. Moreover; some oncologists are now espousing medical therapy as neoadjuvant; adjuvant or even as alternative therapies.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Real-world evidence, Real-world:  Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. (Pubmed Central) -  Jan 5, 2023   
    At time of data cut-off (2021-12), the incidence of HE in sorafenib group (4.2%, 95% CI:2-7%) was significantly lower than that in lenvatinib group (11.3%,95% CI:7-15%) (p = 0.006), with alcoholic cirrhosis [OR: 5.857 (95% CI: 1.519-22.591)], Child-Pugh >7 [OR: 3.023 (95% CI: 1.135-8.053)], blood ammonia ≥38.65 μmol/L [OR: 4.693 (95% CI: 1.782-12.358)], total bile acid ≥29.5 μmol/L [OR: 11.047 (95% CI: 4.414-27.650)] and duration of treatment ≥5.6 months [OR: 4.350 (95% CI: 1.701-11.126)] to be risk factors for the occurrence of HE during first-line systemic therapy. In our study, for off-label uHCC patients (Child-Pugh >7) with alcoholic cirrhosis, hyperammonemia, hypercholesterolemia, and estimated longer duration of treatment, the application of lenvatinib has to be cautious, which needs to be confirmed in future clinical trials.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. (Pubmed Central) -  Jan 3, 2023   
    From first-line therapy, the longest median OS was obtained with the sequence lenvatinib and immunotherapy (47.0 months), followed by TACE (24.7 months), ramucirumab (21.2 months), sorafenib (15.7 months), regorafenib (12.7 months), and best supportive care (10.8 months). Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Endometrial carcinosarcoma. (Pubmed Central) -  Jan 1, 2023   
    In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma.
  • ||||||||||  Journal:  Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. (Pubmed Central) -  Dec 31, 2022   
    Methods and Results Baseline characteristics and BP readings were retrospectively collected from oncology patients who received oral VEGFI treatment (sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, or cabozantinib)...Both calcium channel blockers and renin-angiotensin system inhibitors are effective antihypertensive treatments. Particularly in patients with renal cell carcinoma, a BP rise is associated with improved overall survival.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Dec 29, 2022   
    P1/2,  N=30, Active, not recruiting, 
    Particularly in patients with renal cell carcinoma, a BP rise is associated with improved overall survival. Trial completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date:  CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov) -  Dec 29, 2022   
    P=N/A,  N=474, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), simridarlimab (IBI-322) / Innovent Biologics
    Biomarker, Trial completion date, Trial initiation date:  Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) -  Dec 28, 2022   
    P2,  N=40, Not yet recruiting, 
    Larger studies are needed to validate our results. Trial completion date: Mar 2023 --> Sep 2023 | Initiation date: Jul 2022 --> Jan 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
    Trial completion date, Trial primary completion date, Pan tumor:  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (clinicaltrials.gov) -  Dec 27, 2022   
    P2,  N=610, Recruiting, 
    Patients could continue lenvatinib treatment and receive ICIs as well as locoregional treatment to achieve better OS. Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience. (Pubmed Central) -  Dec 24, 2022   
    The observed incidence in our patient sample seemed to be higher than expected. We hypothesized that our patient sample might be at higher risk probably because of the heavy prior loco-regional treatments performed.
  • ||||||||||  Podcasts for Oncology Nurses Reinforce Knowledge of Treatment Toxicity and Management, Improving Confidence and Competence in Patient Care (Henry B. Gonz) -  Dec 24, 2022 - Abstract #ONS2023ONS_131;    
    Evaluation/ The post-activity assessment demonstrates notable areas of knowledge gain, especially regarding management of dabrafenib/trametinib adverse events (27%) and lenvatinib/pembrolizumab safety (24%). The improvements in competence seen on the case-based assessment questions, as well as gains in self-perceived competence and confidence in treating patients with cancer, show the importance of NCPD for oncology nurses and the educational benefits of a podcast format.
  • ||||||||||  MODULE 2: Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) -  Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_997;    
    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc. Key data informing the rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab for microsatellite instability-high/mismatch repair-deficient mCRC Early results with and ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for MSI-H/dMMR advanced CRC Biologic rationale for the investigation of immune checkpoint inhibition for microsatellite-stable (MSS) mCRC Clinical activity and safety observed with cabozantinib in combination with anti-PD-1/PD-L1 antibodies among patients with MSS mCRC in early-phase trials (eg, COSMIC-021 cohort 16, CAMILLA cohort 2) Pharmacologic and pharmacodynamic comparison of cabozantinib and XL092 Design, eligibility and efficacy and safety endpoints for the Phase III STELLAR-303 trial comparing XL092/atezolizumab to regorafenib for relapsed/refractory (R/R) MSS mCRC Available data with and ongoing investigation of other immune checkpoint inhibitor-based strategies (eg, lenvatinib/pembrolizumab, regorafenib/pembrolizumab) for MSS mCRC Available data with and ongoing investigation of other immune checkpoint inhibitor-based strategies (eg, lenvatinib/pembrolizumab, regorafenib/pembrolizumab) for patients with MSS mCRC
  • ||||||||||  MODULE 2: Selection and Sequencing of Therapies for Relapsed/Refractory HCC (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) -  Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_984;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck. Factors in the selection and sequencing of treatment for patients with advanced HCC whose disease has progressed on first and consecutive lines of therapy Role of multitargeted TKIs approved in the first-line setting (eg, sorafenib, lenvatinib) among patients with relapsed disease Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) among patients with progressive HCC Results from the Phase III KEYNOTE-394 trial and other pivotal studies examining the role of single-agent immune checkpoint inhibitors for relapsed/refractory HCC Key findings with anti-PD-1/PD-L1 and anti-CTLA-4 combination regimens for patients with progressive HCC Other promising agents and strategies currently under investigation for HCC
  • ||||||||||  MODULE 1: First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) (San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)) -  Dec 23, 2022 - Abstract #ASCOGI2023ASCO_GI_983;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck. Long-term findings from the Phase III IMbrave150 study comparing first-line atezolizumab/ bevacizumab to sorafenib for advanced unresectable HCC; patient selection for atezolizumab/ bevacizumab Design, eligibility criteria and key endpoints of the Phase III HIMALAYA trial evaluating durvalumab/ tremelimumab or durvalumab alone versus sorafenib as first-line treatment for unresectable advanced HCC Achievement of an overall survival advantage and other key efficacy outcomes with durvalumab/ tremelimumab in the HIMALAYA trial; recent FDA approval and current clinical role Mechanism of action of tislelizumab; similarities and differences with commercially available anti-PD-1/PD-L1 antibodies Available results from the Phase III RATIONALE 301 trial comparing tislelizumab to sorafenib as first-line treatment for advanced unresectable HCC; potential clinical role Current clinical utility of tyrosine kinase inhibitor (TKI) monotherapy as first-line treatment for unresectable HCC; recently presented findings demonstrating a potential advantage with lenvatinib compared to atezolizumab/bevacizumab for nonviral disease